EP
MYOV

Eversept Partners’s Myovant Sciences Ltd. MYOV Stock Holding History

Eversept Partners’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-760,551
Closed -$15.7M – 71
2020
Q2 		$15.7M Buy
+760,551
New +$10.3M 2.15% 16

Other funds holding MYOV

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Eversept Partners's MYOV Position: Q3 2020 in Review

Eversept Partners sold out of Myovant Sciences Ltd. (MYOV) in Q3 2020, closing a stake of 760,551 shares — an estimated $15.7M sold.

Eversept Partners first reported a position in MYOV in Q2 2020 and held it in 1 quarter. The position peaked at $15.7M in Q2 2020. 102 funds tracked by Wall St. Rank hold MYOV as of Q3 2020.

  • Eversept Partners reported no remaining Myovant Sciences Ltd. position as of Q3 2020 after selling out during the quarter.
  • Eversept Partners sold 760,551 Myovant Sciences Ltd. shares in Q3 2020, an estimated $15.7M.
  • Eversept Partners first reported a position in Myovant Sciences Ltd. in Q2 2020 and held it in 1 quarter.
  • Eversept Partners's Myovant Sciences Ltd. position peaked at $15.7M in Q2 2020.
  • 102 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q3 2020.

Based on Eversept Partners's 13F filing for Q3 2020, filed 12 Nov 2020.